The Latest Breaking News from Johnson & Johnson (

Scientists say there is no evidence to suggest that vaccinations are making COVID "stronger" and that mutations are a normal part of virus evolution.

Johnson & Johnson (JNJ) continued its business momentum in the third quarter of fiscal 2022, driven by steady demand for its products and innovative, advancing portfolio and pipeline. Moreover, the company has a record of raising its dividend for 60 consecutive years. Amid the current uncertain market conditions, this fundamentally…

Johnson & Johnson's consumer health care division, named Kenvue, will have annual sales of around $15 billion.

Stock futures flat as Fed minutes challenge rate bets; Jobs data in focus as Fed highlights wage growth; Johnson & Johnson plans IPO for consumer health care division; Amazon confirms 18,000 layoffs as big tech sheds more jobs and Walgreens earnings on deck with pharmacy sales in focus.

Social media users shared a range of false claims this week

Want to see just how much stocks like Tesla have fallen to pieces? Just look at the new top 10 most valuable S&P 500 firms.

DALLAS — Staying on schedule with the COVID-19 vaccine can feel like chasing a moving target.

Studies in West Africa said the vaccines developed by Johnson & Johnson and Merck & Co appear to be safe in children.

Ebola vaccines developed by Johnson Johnson and Merck Co produced virus-fighting antibodies and appear to be safe in children and adults, according to data from two studies published on Wednesday.

Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushing HZNP stock into the red on Monday.

The legal firm representing the thousands of plaintiffs in a class action over dangerous pelvic mesh could take up to a third of the compensation payment.